Edward D. Nudelman
Cancer Biochemist
Seattle, WA
Profile
Noted scientist and innovator in the field of cancer biochemistry and immunology, with 79 papers in top-tier cancer and biochemical journals relating to structure and function of cancer cells, immuno-targeting, and mechanism of action of various disease processes. Among the first to characterize targets for monoclonal antibodies, with papers describing precise epitopes on binding of key monoclonal antibodies to known immunological sites on cells. Founded LipoMed Corp. in 1994, developing pro-angiogenic factors for wound-healing and vascular disease. In an IP Acquisition, merged LipoMed with a leading Seattle Biotech, Cell Therapeutics, in 1994, becoming head scientist and group leader for this Seattle biotech company, remaining as chief scientist until 2004. Founded Lipidomics, Inc., in 2004, investigating the role of oxidized lipids in cardiovascular disease. First to identify antigen-specific epitope for Burkitt’s Lymphoma (Science, 1983) and ligand for E-Selectin (Science, 1990), also known as CD62 antigen-like family member E (CD62E), a key pathway in inflammation and immunology, endothelial-leukocyte adhesion molecule 1 (ELAM-1). Over thirty years experience in Pharma drug research and development, including ten years at Cell Therapeutics in Seattle, WA, receiving “Scientist of the Year,” in 1998. Program Head, Zymequest Corporation, 2005-9, exploring biochemical basis and research and development of synthetic blood technology. Co-founded Glycozym in 2009, an innovative biotech company working on a single blood test for the detection of cancer, which was later acquired by GoTherapeutics, which is very active in research and development of therapeutics in many disease applications. Currently free-lance consultant, advisor viz startups, scientific intellectual property, vetting.
RESEARCH CITATION STATS (as of July/2021):
Citations: 8,186
RG Score: 37.38
Percentile: Higher than 95%
Papers: 79
AWARDS
Fuji Prize, 1991. Otsuka Pharm (The Biomembrane Institue). “In acknowledgement of a Devotional and Distinguished Contribution,” Outstanding Scientist of the Year.
Scientist of the Year, 1998. The E. Donnall Thomas Award, 1998. Cell Therapeutics Inc. “For Achievements in Science and Technology.”
Rainier Award, 1998. Cell Therapeutics Inc., Humanitarian Award for Community Service.
------------
SCIENTIFIC PUBLICATIONS (chronologically displayed)
and...
(9) Hollenback D, Nudelman E, Romero L, Bonham L, White T. Intracellular activity of lysophosphatidic acid acyltransferase. Keystone Symposium , 124. 2002. Taos, NM.
(10) Shaffer S, Lee CB, Nudelman E, Kumar A, Coon M, Stone I et al. Metabolism of poly-L-glutamic acid (PG) paclitaxl (CT-2103); characterization of metabolites generated through proteolysis by lysosomal Cathepsin B and other cysteine proteases. 2002.
(Several papers submitted and in press with Zymequest Corp. including last paper just accepted into Nature.)
US PATENTS
1) 9/87 US Patent 07/094,459 Hakomori, Nudelman, Singhal.
Detection of survived, undegraded carbohydrate epitope
In feces as diagnostic of colon cancer
2) 5/88 US Patent 07/200,160 Hakomori, Nudelman, Levery, et. al.
A novel long-chain glycolipid structure
3) 1/89 US Patent 07/302,890 Nudelman and Clausen.
Monoclonal antibodies directed to tumor-associated antigens
4) 3/89 US Patent 07/320,682 Hakomori, Nudelman and Singhal.
Detection of survived, undegraded carbohydrate epitopes as diagnostic of intestinal disease
5) 4/89 US Patent 07/344,628 Nudelman, Clausen and Hakomori.
Bioorganic synthesis of dimeric Lex
6) 5/91 US Patent 07/695,506 Stroud, Levery, Nudelman.
Extended type 1 chain glycosphingolipids as tumor-associated antigens
7) 11/91 US Patent 07/789,969 Handa, Nudelman and Hakomori.
Identification of carbohydrate epitopes for CD62.
University Experience
1971-1975 University of Washington
B.S., Department of Zoology, honors
1975-1976 University of Washington
B.S., Dept. of Chemistry,(honors)
Research/Professional Experience
Apr 2009-Present Head Scientist and Co-Founder, Glycoyzm developing cancer diagnostics
Sep 05- 2009 Head of Program
Chief Scientist, Lipid Biochemistry
Zymequest Corporation, Beverly, MA
-Head up program involved in the
isolation and characterization of
red blood cell epitopes on all
blood groups responsible for
incompatible crossmatch activity.
-Determined major blood group
incompatibility (H-A) in enzyme
treated rbc’s just prior to clinical
-Produced complex array systems
of molecularly defined carbohydrate
epitopes on human RBCS
Jan 95 – Sept 05 Chief Scientist, Analytical Lipid Biochemistry, Cell Therapeutics, Inc., Seattle, WA
-Developed proprietary methods for separation,
identification and quantification of virtually every phospholipid and neutral lipid species in
mammalian tissues
-Managed state-of-art analytical lipid lab capable of analyzing high-throughput assays for
quantification of nanomole quantities of lipid species
-Chiefly responsible for identification of
mechanism of action of the company’s lead clinical compound, Apra, a highly effective, novel
chemotherapeutic agent
-Developed novel and state-of-art lipid analytical technology allowing the detection of nanomole
quantities of oxidized lipids in human sera and plasma. Rigourously validated this technology for
the rapid and high-throughput analysis of plasma lipids.
-Developed assay systems for rapid and high throughput screening of discovery compounds using lipid
enzymes and specific radio-labelled substrates. Identified key pathways and mechanism of action
for company’s lead inhibitor for novel cancer target.
-Designed and validated assay system showing reduction of oxidized lipids in in vitro systems with
Company’s lead compounds.
Jan 93 - Mar 94 Sole Founder, Head Scientist, Lipomed Corp., Seattle, WA
-Novel research and development of lipid angiogenic factors isolated from human omentum
-Identification of molecular lipid species causing microvessel growth of human endothelial cells
-In vivo models for angiogenesis
-Proprietary patents written, approved for method of use, pro-angiogenic factors. Sold
technology to CTI (see below)
Oct 86 – Dec 94 Head Scientist and Co-Founder, The Biomembrane Institute, Seattle, WA, with Dr. Hakomori
-Shigella toxin-binding glycolipids
-Identification and characterization of novel tumor-associated glycolipids
-First elucidation of CD-62 and ELAM-1 receptors as glycolipid antigens
-Novel glycolipids in human brain as nerve cell mitogens
-Uropathogenic E. coli binding to novel glycolipids from vaginal epithelia
Jan 81 - Sept 86 Staff Scientist
Fred Hutchinson Cancer Research Center
-Identification of glycolipid as key Burkitt lymphoma-specific tumor associated antigen
-Glycosphingolipid metabolism and
identification in cancer
-Collagen binding proteins on sperm
-Monoclonal antibodies associated with cancer
Jan 78 - Dec 80 Research Associate
Fred Hutchinson Cancer Research Center
-Blood group antigens
-Tumor associated glycosphingolipids
Pharma Specific Experience
CO-FOUNDER, THE BIOMEMBRANE INSTITUTE
6/86- 12/94
Co-founded, with Dr. Sen-Itiroh Hakomori, The Biomembrane Institute in Seattle, WA, with 4M dollars seed money from Otsuka Pharmaceuticals, 3rd leading pharmaceutical company in Japan. Helped develop lipid research program elucidating tumor-associated glycolipid markers. Performed research and helped write over a dozen patents involving anti-cancer strategies for therapy and diagnostics.
DIRECTOR OF ONCOMEMBRANE SEATTLE
3/91- 2/92
Director and chief scientific officer of corporation start-up venture chartered by Otsuka to act as developing arm for patents produced by Biomembrane Institute.
FOUNDER, LIPOMED CORP.
1/93- 3/94
Obtained private capitalization of $700,000 and founded biotechnology company aimed at purifying lipid angiogenic factors from human omentum. Assembled staff of Ph.D.’s and leased research lab space for dedicated biochemical research. Isolated lipid angiogenic factor and submitted patents. Sold technology to Cell Therapeutics (CTI), and currently continuing the lipid angiogenic research as employee of CTI.
GROUP LEADER, ANALYTICAL LIPID BIOCHEMISTRY, CTI
1/95- present
Member of IND team to bring company’s lead product, Apra, to clinic. Group leader of lipid analysis responsible for elucidating the mechanism of action of the drug.
GROUP LEADER, LIPID ANGIOGENESIS, CTI 1/95- present
Managed collaborations with three separate research institutions performing in vitro and in vivo studies assaying the structure to function relationships of various lipid angiogenic molecules ($200,000 budget).
GROUP LEADER, METABOLITES OF LYSOFYLLINE, CTI
3/97-2/98
Led research and development leading to identification of novel
intellectual property defining the in vivo metabolites of one of the company’s lead compounds, Lisofylline.
MEMBER, PROJECT TEAM, OXIDIZED LIPIDS IN HUMAN SERUM, CTI
4/97-7/05
Developed proprietary extraction protocol and novel thin layer
chromatography (TLC) technology leading to a fascile and very
sensitve assay for the detection of oxidized lipids in human plasma.
PROGRAM HEAD, ZYMEQUEST CORPORATION
9/05-6/08
Organized, developed and implemented program for biochemical
analysis of surface lipids on rbc’s including all immunological assays
and state-of-art techniques.
HEAD SCIENTIST AND CO-FOUNDER, GLYCOZYM INC
6/08 to present
World-leader in tumor-markers and early diagnosis of cancer with a simple blood test.
Please view our website for details: http://www.glycozym.com/
*********
AWARDS
Fuji Prize, 1991. Otsuka Pharm (The Biomembrane Institue). “In acknowledgement of a Devotional and Distinguished Contribution,” Outstanding Scientist of the Year.
Scientist of the Year, 1998. The E. Donnall Thomas Award, 1998. Cell Therapeutics Inc. “For Achievements in Science and Technology.”
Rainier Award, 1998. Cell Therapeutics Inc., Humanitarian Award for Community Service.
------------
SCIENTIFIC PUBLICATIONS (chronologically displayed)
1
|
Liu QP, Yuan H, Bennett EP, Levery SB, Nudelman E, Spence J, Pietz G, Saunders K, White T, Olsson ML, Henrissat B, Sulzenbacher G, Clausen H.
|
J Biol Chem. 2008 Mar 28;283(13):8545-54. doi: 10.1074/jbc.M709020200. Epub 2008 Jan 28.
|
Select item 174013603.
|
2
|
Liu QP, Sulzenbacher G, Yuan H, Bennett EP, Pietz G, Saunders K, Spence J, Nudelman E, Levery SB, White T, Neveu JM, Lane WS, Bourne Y, Olsson ML, Henrissat B, Clausen H.
|
Nat Biotechnol. 2007 Apr;25(4):454-64. Epub 2007 Apr 1.
|
Select item 110166494.
|
3
|
Finney RE, Nudelman E, White T, Bursten S, Klein P, Leer LL, Wang N, Waggoner D, Singer JW, Lewis RA.
|
Cancer Res. 2000 Sep 15;60(18):5204-13.
|
4
|
White T, Bursten S, Federighi D, Lewis RA, Nudelman E.
|
Anal Biochem. 1998 Apr 10;258(1):109-17.
|
5
|
Bursten SL, Federighi D, Wald J, Meengs B, Spickler W, Nudelman E.
|
J Pharmacol Exp Ther. 1998 Jan;284(1):337-45.
|
6
|
West J, Tompkins CK, Balantac N, Nudelman E, Meengs B, White T, Bursten S, Coleman J, Kumar A, Singer JW, Leung DW.
|
DNA Cell Biol. 1997 Jun;16(6):691-701.
|
7
|
Weeks R, Dowhan W, Shen H, Balantac N, Meengs B, Nudelman E, Leung DW.
|
DNA Cell Biol. 1997 Mar;16(3):281-9.
|
8
|
Abdel-Wahab Z, Li WP, Darrow T, Nudelman ED, Towell A, Seigler HF.
|
Melanoma Res. 1993 Dec;3(6):415-23.
|
9
|
Dohi T, Nemoto T, Ohta S, Shitara K, Hanai N, Nudelman E, Hakomori S, Oshima M.
|
Anticancer Res. 1993 Sep-Oct;13(5A):1277-82.
|
10
|
Sadozai KK, Anand JK, Nudelman ED, Hakomori S.
|
Carbohydr Res. 1993 Mar 17;241:301-7. No abstract available.
|
11
|
Stapleton A, Nudelman E, Clausen H, Hakomori S, Stamm WE.
|
J Clin Invest. 1992 Sep;90(3):965-72.
|
12
|
Levery SB, Nudelman ED, Hakomori S.
|
Biochemistry. 1992 Jun 16;31(23):5335-40.
|
13
|
Nudelman ED, Levery SB, Igarashi Y, Hakomori S.
|
J Biol Chem. 1992 Jun 5;267(16):11007-16.
|
14
|
Jagirdar J, Thung SN, Shah KD, Nudelman E, Singhal A, Paronetto F.
|
Arch Pathol Lab Med. 1992 Jun;116(6):643-8.
|
15
|
Handa K, Nudelman ED, Stroud MR, Shiozawa T, Hakomori S.
|
Biochem Biophys Res Commun. 1991 Dec 31;181(3):1223-30.
|
16
|
Petry K, Greinix HT, Nudelman E, Eisen H, Hakomori S, Levy HL, Reichardt JK.
|
Biochem Med Metab Biol. 1991 Aug;46(1):93-104.
|
17
|
Polley MJ, Phillips ML, Wayner E, Nudelman E, Singhal AK, Hakomori S, Paulson JC.
|
Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6224-8.
|
18
|
Stroud MR, Levery SB, Nudelman ED, Salyan ME, Towell JA, Roberts CE, Watanabe M, Hakomori S.
|
J Biol Chem. 1991 May 5;266(13):8439-46.
|
19
|
Matsushita Y, Hoff SD, Nudelman ED, Otaka M, Hakomori S, Ota DM, Cleary KR, Irimura T.
|
Clin Exp Metastasis. 1991 May-Jun;9(3):283-99.
|
20
|
Watanabe M, Ohishi T, Kuzuoka M, Nudelman ED, Stroud MR, Kubota T, Kodairo S, Abe O, Hirohashi S, Shimosato Y, et al.
|
Cancer Res. 1991 Apr 15;51(8):2199-204.
|
21
|
Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, Hakomori S, Paulson JC.
|
Science. 1990 Nov 23;250(4984):1130-2.
|
22
|
Hanai N, Shitara K, Furuya A, Yoshida H, Dohi T, Nudelman E, Hakomori S, Satoh S.
|
Anticancer Res. 1990 Nov-Dec;10(6):1579-86.
|
23
|
Ohyama C, Fukushi Y, Satoh M, Saitoh S, Orikasa S, Nudelman E, Straud M, Hakomori S.
|
Int J Cancer. 1990 Jun 15;45(6):1040-4.
|
24
|
Andrews PW, Nudelman E, Hakomori S, Fenderson BA.
|
Differentiation. 1990 Apr;43(2):131-8.
|
25
|
Singhal AK, Orntoft TF, Nudelman E, Nance S, Schibig L, Stroud MR, Clausen H, Hakomori S.
|
Cancer Res. 1990 Mar 1;50(5):1375-80.
|
26
|
Bailey GB, Nudelman ED, Day DB, Gilmour JR, Harper CF.
|
Arch Invest Med (Mex). 1990;21 Suppl 1:85-9.
|
27
|
Bailey GB, Nudelman ED, Day DB, Harper CF, Gilmour JR.
|
Infect Immun. 1990 Jan;58(1):43-7.
|
28
|
Zhu Z, Deng H, Fenderson BA, Nudelman ED, Tsui Z.
|
J Reprod Fertil. 1990 Jan;88(1):71-9.
|
29
|
Kyogashima M, Mulshine J, Linnoila RI, Jensen S, Magnani JL, Nudelman E, Hakomori S, Ginsburg V.
|
Arch Biochem Biophys. 1989 Nov 15;275(1):309-14.
|
30
|
Nudelman ED, Mandel U, Levery SB, Kaizu T, Hakomori S.
|
J Biol Chem. 1989 Nov 5;264(31):18719-25.
|
31
|
Miyake M, Kohno N, Nudelman ED, Hakomori S.
|
Cancer Res. 1989 Oct 15;49(20):5689-95.
|
32
|
Levery SB, Nudelman ED, Salyan ME, Hakomori S.
|
Biochemistry. 1989 Sep 19;28(19):7772-81.
|
33
|
Nudelman ED, Levery SB, Stroud MR, Salyan ME, Abe K, Hakomori S.
|
J Biol Chem. 1988 Sep 25;263(27):13942-51.
|
34
|
Petry K, Nudelman E, Eisen H, Hakomori S.
|
Mol Biochem Parasitol. 1988 Aug;30(2):113-21.
|
35
|
Levery SB, Nudelman E, Kannagi R, Symington FW, Andersen NH, Clausen H, Baldwin M, Hakomori S.
|
Carbohydr Res. 1988 Jul 15;178:121-44.
|
36
|
Tsuji Y, Clausen H, Nudelman E, Kaizu T, Hakomori S, Isojima S.
|
J Exp Med. 1988 Jul 1;168(1):343-56.
|
37
|
Singhal AK, Singhal MC, Nudelman E, Hakomori S, Balint JP, Grant CK, Snyder HW Jr.
|
Cancer Res. 1987 Nov 1;47(21):5566-71.
|
38
|
Clausen H, Levery SB, Nudelman ED, Stroud M, Salyan ME, Hakomori S.
|
J Biol Chem. 1987 Oct 15;262(29):14228-34.
|
39
|
Fenderson BA, Andrews PW, Nudelman E, Clausen H, Hakomori S.
|
Dev Biol. 1987 Jul;122(1):21-34.
|
40
|
Clausen H, Levery SB, Nudelman E, Baldwin M, Hakomori S.
|
Biochemistry. 1986 Nov 4;25(22):7075-85.
|
41
|
Nudelman E, Levery SB, Kaizu T, Hakomori S.
|
J Biol Chem. 1986 Aug 25;261(24):11247-53.
|
42
|
Kaizu T, Levery SB, Nudelman E, Stenkamp RE, Hakomori S.
|
J Biol Chem. 1986 Aug 25;261(24):11254-8.
|
44
|
Levery SB, Nudelman ED, Andersen NH, Hakomori S.
|
Carbohydr Res. 1986 Aug 15;151:311-28.
|
45
|
Jacewicz M, Clausen H, Nudelman E, Donohue-Rolfe A, Keusch GT.
|
J Exp Med. 1986 Jun 1;163(6):1391-404.
|
46
|
Hirohashi S, Clausen H, Nudelman E, Inoue H, Shimosato Y, Hakomori S.
|
J Immunol. 1986 Jun 1;136(11):4163-8.
|
47
|
Fukushi Y, Nudelman E, Levery SB, Higuchi T, Hakomori S.
|
Biochemistry. 1986 May 20;25(10):2859-66.
|
48
|
Nudelman E, Fukushi Y, Levery SB, Higuchi T, Hakomori S.
|
J Biol Chem. 1986 Apr 25;261(12):5487-95.
|
49
|
Clausen H, Levery SB, Nudelman E, Tsuchiya S, Hakomori S.
|
Proc Natl Acad Sci U S A. 1985 Feb;82(4):1199-203.
|
50
|
Fukushima K, Hirota M, Terasaki PI, Wakisaka A, Togashi H, Chia D, Suyama N, Fukushi Y, Nudelman E, Hakomori S.
|
Cancer Res. 1984 Nov;44(11):5279-85.
|
51
|
Clausen H, Watanabe K, Kannagi R, Levery SB, Nudelman E, Arao-Tomono Y, Hakomori S.
|
Biochem Biophys Res Commun. 1984 Oct 30;124(2):523-9.
|
52
|
Fukushi Y, Nudelman E, Levery SB, Hakomori S, Rauvala H.
|
J Biol Chem. 1984 Aug 25;259(16):10511-7.
|
53
|
Hakomori S, Nudelman E, Levery SB, Kannagi R.
|
J Biol Chem. 1984 Apr 10;259(7):4672-80.
|
54
|
Fukushi Y, Hakomori S, Nudelman E, Cochran N.
|
J Biol Chem. 1984 Apr 10;259(7):4681-5.
|
55
|
Hakomori S, Patterson CM, Nudelman E, Sekiguchi K.
|
J Biol Chem. 1983 Oct 10;258(19):11819-22.
|
56
|
Hakomori S, Nudelman E, Levery SB, Patterson CM.
|
Biochem Biophys Res Commun. 1983 Jun 29;113(3):791-8.
|
57
|
Nudelman E, Kannagi R, Hakomori S, Parsons M, Lipinski M, Wiels J, Fellous M, Tursz T.
|
Science. 1983 Apr 29;220(4596):509-11.
|
58
|
Kannagi R, Nudelman E, Levery SB, Hakomori S.
|
J Biol Chem. 1982 Dec 25;257(24):14865-74.
|
59
|
Hakomori S, Nudelman E, Kannagi R, Levery SB.
|
Biochem Biophys Res Commun. 1982 Nov 16;109(1):36-44. No abstract available.
|
60
|
Nudelman E, Hakomori S, Kannagi R, Levery S, Yeh MY, Hellström KE, Hellström I.
|
J Biol Chem. 1982 Nov 10;257(21):12752-6.
|
61
|
Lipinski M, Nudelman ED, Wiels J, Parsons M.
|
J Immunol. 1982 Nov;129(5):2301-4.
|
62
|
Kannagi R, Nudelman E, Hakomori S.
|
Proc Natl Acad Sci U S A. 1982 Jun;79(11):3470-4.
|
63
|
Hakomori S, Nudelman E, Levery S, Solter D, Knowles BB.
|
Biochem Biophys Res Commun. 1981 Jun;100(4):1578-86. No abstract available.
|
64
|
Nudelman E, Hakomori S, Knowles BB, Solter D, Nowinski RC, Tam MR, Young WW Jr.
|
Biochem Biophys Res Commun. 1980 Nov 28;97(2):443-51. No abstract available.
|
65
|
Koehler JK, Nudelman ED, Hakomori S.
|
J Cell Biol. 1980 Aug;86(2):529-36.
|
66
|
Koyama K, Nudelman E, Fukuda M, Hakomori S.
|
Cancer Res. 1979 Sep;39(9):3677-82. No abstract available.
|
67
|
Baumann H, Nudelman E, Watanabe K, Hakomori S.
|
Cancer Res. 1979 Jul;39(7 Pt 1):2637-43.
|
(9) Hollenback D, Nudelman E, Romero L, Bonham L, White T. Intracellular activity of lysophosphatidic acid acyltransferase. Keystone Symposium , 124. 2002. Taos, NM.
(10) Shaffer S, Lee CB, Nudelman E, Kumar A, Coon M, Stone I et al. Metabolism of poly-L-glutamic acid (PG) paclitaxl (CT-2103); characterization of metabolites generated through proteolysis by lysosomal Cathepsin B and other cysteine proteases. 2002.
(Several papers submitted and in press with Zymequest Corp. including last paper just accepted into Nature.)
US PATENTS
1) 9/87 US Patent 07/094,459 Hakomori, Nudelman, Singhal.
Detection of survived, undegraded carbohydrate epitope
In feces as diagnostic of colon cancer
2) 5/88 US Patent 07/200,160 Hakomori, Nudelman, Levery, et. al.
A novel long-chain glycolipid structure
3) 1/89 US Patent 07/302,890 Nudelman and Clausen.
Monoclonal antibodies directed to tumor-associated antigens
4) 3/89 US Patent 07/320,682 Hakomori, Nudelman and Singhal.
Detection of survived, undegraded carbohydrate epitopes as diagnostic of intestinal disease
5) 4/89 US Patent 07/344,628 Nudelman, Clausen and Hakomori.
Bioorganic synthesis of dimeric Lex
6) 5/91 US Patent 07/695,506 Stroud, Levery, Nudelman.
Extended type 1 chain glycosphingolipids as tumor-associated antigens
7) 11/91 US Patent 07/789,969 Handa, Nudelman and Hakomori.
Identification of carbohydrate epitopes for CD62.
University Experience
1971-1975 University of Washington
B.S., Department of Zoology, honors
1975-1976 University of Washington
B.S., Dept. of Chemistry,(honors)
Research/Professional Experience
Apr 2009-Present Head Scientist and Co-Founder, Glycoyzm developing cancer diagnostics
Sep 05- 2009 Head of Program
Chief Scientist, Lipid Biochemistry
Zymequest Corporation, Beverly, MA
-Head up program involved in the
isolation and characterization of
red blood cell epitopes on all
blood groups responsible for
incompatible crossmatch activity.
-Determined major blood group
incompatibility (H-A) in enzyme
treated rbc’s just prior to clinical
-Produced complex array systems
of molecularly defined carbohydrate
epitopes on human RBCS
Jan 95 – Sept 05 Chief Scientist, Analytical Lipid Biochemistry, Cell Therapeutics, Inc., Seattle, WA
-Developed proprietary methods for separation,
identification and quantification of virtually every phospholipid and neutral lipid species in
mammalian tissues
-Managed state-of-art analytical lipid lab capable of analyzing high-throughput assays for
quantification of nanomole quantities of lipid species
-Chiefly responsible for identification of
mechanism of action of the company’s lead clinical compound, Apra, a highly effective, novel
chemotherapeutic agent
-Developed novel and state-of-art lipid analytical technology allowing the detection of nanomole
quantities of oxidized lipids in human sera and plasma. Rigourously validated this technology for
the rapid and high-throughput analysis of plasma lipids.
-Developed assay systems for rapid and high throughput screening of discovery compounds using lipid
enzymes and specific radio-labelled substrates. Identified key pathways and mechanism of action
for company’s lead inhibitor for novel cancer target.
-Designed and validated assay system showing reduction of oxidized lipids in in vitro systems with
Company’s lead compounds.
Jan 93 - Mar 94 Sole Founder, Head Scientist, Lipomed Corp., Seattle, WA
-Novel research and development of lipid angiogenic factors isolated from human omentum
-Identification of molecular lipid species causing microvessel growth of human endothelial cells
-In vivo models for angiogenesis
-Proprietary patents written, approved for method of use, pro-angiogenic factors. Sold
technology to CTI (see below)
Oct 86 – Dec 94 Head Scientist and Co-Founder, The Biomembrane Institute, Seattle, WA, with Dr. Hakomori
-Shigella toxin-binding glycolipids
-Identification and characterization of novel tumor-associated glycolipids
-First elucidation of CD-62 and ELAM-1 receptors as glycolipid antigens
-Novel glycolipids in human brain as nerve cell mitogens
-Uropathogenic E. coli binding to novel glycolipids from vaginal epithelia
Jan 81 - Sept 86 Staff Scientist
Fred Hutchinson Cancer Research Center
-Identification of glycolipid as key Burkitt lymphoma-specific tumor associated antigen
-Glycosphingolipid metabolism and
identification in cancer
-Collagen binding proteins on sperm
-Monoclonal antibodies associated with cancer
Jan 78 - Dec 80 Research Associate
Fred Hutchinson Cancer Research Center
-Blood group antigens
-Tumor associated glycosphingolipids
Pharma Specific Experience
CO-FOUNDER, THE BIOMEMBRANE INSTITUTE
6/86- 12/94
Co-founded, with Dr. Sen-Itiroh Hakomori, The Biomembrane Institute in Seattle, WA, with 4M dollars seed money from Otsuka Pharmaceuticals, 3rd leading pharmaceutical company in Japan. Helped develop lipid research program elucidating tumor-associated glycolipid markers. Performed research and helped write over a dozen patents involving anti-cancer strategies for therapy and diagnostics.
DIRECTOR OF ONCOMEMBRANE SEATTLE
3/91- 2/92
Director and chief scientific officer of corporation start-up venture chartered by Otsuka to act as developing arm for patents produced by Biomembrane Institute.
FOUNDER, LIPOMED CORP.
1/93- 3/94
Obtained private capitalization of $700,000 and founded biotechnology company aimed at purifying lipid angiogenic factors from human omentum. Assembled staff of Ph.D.’s and leased research lab space for dedicated biochemical research. Isolated lipid angiogenic factor and submitted patents. Sold technology to Cell Therapeutics (CTI), and currently continuing the lipid angiogenic research as employee of CTI.
GROUP LEADER, ANALYTICAL LIPID BIOCHEMISTRY, CTI
1/95- present
Member of IND team to bring company’s lead product, Apra, to clinic. Group leader of lipid analysis responsible for elucidating the mechanism of action of the drug.
GROUP LEADER, LIPID ANGIOGENESIS, CTI 1/95- present
Managed collaborations with three separate research institutions performing in vitro and in vivo studies assaying the structure to function relationships of various lipid angiogenic molecules ($200,000 budget).
GROUP LEADER, METABOLITES OF LYSOFYLLINE, CTI
3/97-2/98
Led research and development leading to identification of novel
intellectual property defining the in vivo metabolites of one of the company’s lead compounds, Lisofylline.
MEMBER, PROJECT TEAM, OXIDIZED LIPIDS IN HUMAN SERUM, CTI
4/97-7/05
Developed proprietary extraction protocol and novel thin layer
chromatography (TLC) technology leading to a fascile and very
sensitve assay for the detection of oxidized lipids in human plasma.
PROGRAM HEAD, ZYMEQUEST CORPORATION
9/05-6/08
Organized, developed and implemented program for biochemical
analysis of surface lipids on rbc’s including all immunological assays
and state-of-art techniques.
HEAD SCIENTIST AND CO-FOUNDER, GLYCOZYM INC
6/08 to present
World-leader in tumor-markers and early diagnosis of cancer with a simple blood test.
Please view our website for details: http://www.glycozym.com/
*********
